GreenDot Stocks
Back to screen

Arcutis Biotherapeutics (ARQT)

Red Dot

Statistics

MetricValue
Last Close$28.26
Blended Price Target28.29
Blended Margin of Safety0.1% Fairly Valued
Rule of 40 (Next)46.4%
Rule of 40 (Current)60.7%
FCF-ROIC16.7%
Sales Growth Next Year29.7%
Sales Growth Current Year44.0%
Sales 3-Year Avg117.9%
IndustryBiotechnology

Analysis

Arcutis is a high-quality commercial-stage dermatology company with an unusually focused growth engine. Its lead product, ZORYVE, is expanding rapidly across several common inflammatory skin conditions, and third-quarter 2026 net product revenue reached $143.9 million, up 45% year over year and 11% sequentially.[1] That performance supports a durable growth outlook, although sustaining it will require continued adoption beyond early prescribers and successful expansion into additional indications.

Revenue is transactional rather than contractual or subscription-based, but recurring in an economic sense because chronic dermatology patients often require ongoing treatment. The business has a meaningful commercial moat from regulatory approvals, clinical evidence, physician familiarity, and insurance access, though these advantages are not unassailable. Leadership appears execution-oriented: management has translated a single active ingredient into multiple products while advancing a pipeline that includes vitiligo, hidradenitis suppurativa, and the ARQ-234 biologic program.[1][7] Overall, Arcutis looks like a focused, increasingly diversified specialty-pharmaceutical business, with durability dependent on lifecycle execution and competitive differentiation.

What the Company Does

Arcutis develops and commercializes medicines for inflammatory dermatologic diseases. Its primary commercial platform is ZORYVE, a topical phosphodiesterase-4 inhibitor formulated for conditions including plaque psoriasis, seborrheic dermatitis, and atopic dermatitis. The company makes money by selling approved products through wholesalers, pharmacies, and other healthcare channels.

Recent revenue is overwhelmingly concentrated in ZORYVE rather than spread across separate business segments. In the third quarter of 2026, reported product revenue included ZORYVE foam, creams at multiple strengths, and other ZORYVE formulations; the foam was the largest individual contributor at $75.1 million.[1] Arcutis also retains longer-term optionality from pipeline programs and potential additional ZORYVE indications.

Revenue Recurrence & Predictability

Arcutis does not have subscription revenue, multiyear contracts, or a recurring-revenue percentage to report. Sales are generated when prescriptions are filled, making revenue technically transactional and exposed to prescription volume, refills, payer coverage, and patient persistence.

The underlying demand can nevertheless be relatively repeatable because the company treats chronic skin diseases rather than one-time conditions. Predictability is improving as multiple ZORYVE products address different patient groups, but the business remains dependent on commercial execution and reimbursement. A single-product commercial base also creates greater forecasting sensitivity than a mature portfolio with several independent franchises.

Revenue Growth Durability

ZORYVE’s growth runway appears substantial because Arcutis is still building penetration in large dermatology markets and has broadened the product beyond its initial indication. Management reported growth across all products in the third quarter of 2026, suggesting that expansion is not confined to one formulation.[1] Additional potential indications, including vitiligo and hidradenitis suppurativa, could extend the platform’s useful life if clinical and regulatory outcomes are favorable.

The principal growth levers are physician adoption, payer access, increased awareness, new formulations, and label expansion. Structural support comes from the prevalence of chronic inflammatory skin diseases and demand for effective nonsteroidal treatments. Headwinds include competition from established topical therapies, branded and generic alternatives, formulary restrictions, and the possibility that incremental growth becomes harder as the commercial base expands.

Economic Moat

Arcutis’s moat is primarily intangible rather than cost-based. Regulatory approvals, clinical data, differentiated formulations, manufacturing know-how, and physician experience create barriers that generic competitors cannot immediately replicate. ZORYVE’s multiple strengths and formulations also allow Arcutis to tailor treatment to different disease severities, body areas, and patient populations.

The moat is potentially widening while the company adds indications and builds commercial familiarity, but it is not protected by network effects or high switching costs. Patients and prescribers can move among topical therapies, particularly where insurers impose step edits or high out-of-pocket costs. The strongest protection therefore comes from sustained clinical differentiation and a broader approved franchise, not from structural exclusivity alone.

Management & Leadership

Arcutis is not founder-led in the conventional sense. Chief Executive Officer Brian Schoelkopf has led the company through the transition from development-stage biotechnology to commercial execution, including the launch and expansion of ZORYVE. The recent results indicate effective progress in turning one pharmacologic platform into a growing product family.[1]

Recent public materials do not provide a sufficiently current, reliable insider-ownership figure for inclusion under the requested reporting-period standard. Capital allocation has centered on commercial investment, regulatory development, clinical expansion, and pipeline advancement rather than unrelated diversification. That focus is appropriate for a company still extending its first major franchise.

Key Risks

The greatest business risk is concentration. ZORYVE currently supplies the commercial engine, so weaker-than-expected demand, unfavorable reimbursement, safety concerns, manufacturing disruption, or disappointing label expansion could affect the entire company. The third-quarter 2026 release confirms strong current momentum, but it does not eliminate dependence on one principal platform.[1]

Competition is also material. Dermatology patients can often choose among topical steroids, nonsteroidal therapies, biologics, generics, and newer branded treatments. Competitors may offer lower cost, stronger efficacy in particular populations, or simpler reimbursement pathways. Arcutis must keep demonstrating differentiated clinical and practical benefits to preserve prescribing momentum.

Pipeline and regulatory execution create additional uncertainty. Potential ZORYVE expansions and ARQ-234 could broaden the business, but clinical trials may fail, regulatory decisions may be delayed, or commercial launches may require greater spending than anticipated. The company also faces the ordinary operational demands of scaling a specialty-pharmaceutical sales organization while maintaining reliable supply and payer access.


Sources

  1. https://investors.arcutis.com/news-releases/news-release-details/arcutis-announces-third-quarter-2026-financial-results-and/
  2. https://investors.arcutis.com/investor-relations
  3. https://investors.arcutis.com/static-files/40705651-2149-42db-87e5-d5fb8ff5a3c2
  4. https://investors.arcutis.com/events/event-details/arcutis-biotherapeutics-inc-q3-2026-earnings-conference-call/
  5. https://investors.arcutis.com/financial-information/quarterly-results/
  6. https://investors.arcutis.com/news-and-presentations/events-and-presentations/
  7. https://investors.arcutis.com/static-files/616f63e6-7ad2-4ed9-9357-2cb899143954
  8. https://investors.arcutis.com/static-files/0631a3f1-343a-4dfe-8a28-c56c91b67eed
  9. https://investors.arcutis.com/static-files/8a0a162b-5f6a-42c6-baef-78964a24f8a3
  10. https://investors.arcutis.com/static-files/b3945b4f-3406-4b98-a98f-90ec1bacad9c